

Predictors of Colectomy in Acute Severe Ulcerative Colitis

Lower 95%

Upper

95% CI

5.64

Shreyak Sharma, MD¹, Darrick K. Li, MD PhD², Louis J. Levine, MD MEd¹, Abdelkader Chaar, MD¹, Chandler McMillan, BS¹, Jill K. J. Gaidos, MD², Deborah D. Proctor, MD², Badr Al-Bawardy, MD²

¹Department of Medicine, Yale School of Medicine; ²Section of Digestive Diseases, Department of Medicine, Yale School of Medicine

BACKGROUND

- Up to 30% patients with acute severe ulcerative colitis (ASUC) require a colectomy
- We aimed to identify risk factors for colectomy in a cohort of ASUC patients from a large tertiary academic medical center

MATERIAL & METHODS

- Single-center, retrospective study of all patients hospitalized with ASUC between 01/01/2012-11/01/2021
- ASUC defined by the modified Truelove and Witts criteria
- Patients who underwent colectomy (during hospitalization or after discharge) were compared to patients who did not undergo colectomy
- Continuous variables were analyzed using unpaired student's ttest
- Categorical variables were analyzed using a chi-square test
- Variables with p<0.05 on univariate analysis were identified and incorporated in a multivariate regression model

RESULTS

- 168 patients (52.4% males; mean age 39.8 \pm 17.2 yrs) were included
- Median disease duration was 2.5 years (IQR 1-10)
- 64.9% (n=109) of the cohort were biologic naïve
- 18.5% (n=31) required a colectomy
- Median follow-up time in the colectomy group was 26 months (IQR 11-56) compared to 25 months (IQR 12-48) in the group without colectomy
- Female sex (70.9% vs 42.3%, p=0.04) and oral corticosteroids on admission (70.9% vs 48.9%, p=0.02) were associated with colectomy
- Lower mean hemoglobin (10.5 vs 12 g/dl, p=0.002) and lower mean albumin levels (3.2 vs 3.5 g/dl, p=0.015) were also associated with colectomy
- Patients who were biologic naïve on admission were less likely to have a colectomy (41.9% vs 70.1 %, p=0.003)

Variables	Colectomy (n=31)	No colectomy (n=137)	p-value
Patient characteristics			
Age, mean (SD)	40.5 (19.7)	39.6 (16.7)	0.82
Female, n (%)	22 (70.9)	58 (42.3)	0.004
Disease activity			
Pancolitis, n (%)	20 (64.5)	97 (70.8)	0.75
Disease duration in years, mean (SD)	6.3 (7.9)	6.9 (9.4)	0.71
Presence of extraintestinal manifestations, n (%)	1 (3.2)	12 (8.8)	0.29
Smoking, n (%)	2 (6.5)	7 (5.1)	0.58
Concomitant CMV infection, n (%)	2 (6.5)	1 (0.7)	0.08
Concomitant C. difficile infection, n (%)	1 (3.2)	8 (5.8)	0.56
Labs at presentation			
Hemoglobin g/dL, mean (SD)	10.5 (2.2)	12.0 (2.6)	0.002
C-reactive protein md/dL, mean (SD)	85.7 (61.2)	80.4 (84.9)	0.73
Albumin g/dL, mean (SD)	3.2 (0.7)	3.5 (0.6)	0.015
Medications			
Biologic naïve at time of presentation, n (%)	13 (41.9)	96 (70.1)	0.003
Inpatient infliximab rescue, n (%)	16 (51.6)	51 (37.2)	0.14
On oral corticosteroid at time of admission, n (%)	22 (70.9)	67 (48.9)	0.026
Statins on admission, n (%)	4 (12.9)	9 (6.6)	0.44
Chronic outpatient opioid use, n (%)	3 (9.7)	10 (7.3)	0.65
Inpatient opioid use, n (%)	17 (54.8)	72 (52.6)	0.82
On IMM on admission, n (%)	1 (3.2)	13 (9.5)	0.25

IMM: immunomodulator

 Low albumin (<3.5 g/dL)</th>
 2.22
 0.092
 0.87

 Low hemoglobin (<12 g/dL)</th>
 3.23
 0.014
 1.27

 Female sex
 3.05
 0.018
 1.21

Multivariate logistic regression model included sex, oral

odds of colectomy (OR 3.05, p=0.018).

corticosteroids on admission, hemoglobin <12 g/dL, albumin <3.5

g/dL, and prior biologic exposure at the time of presentation.

• Female sex was independently associated with a 3-fold increased

Hemoglobin level on presentation <12 g/dL was also associated

with a 3-fold increased risk of colectomy (OR 3.23, p=0.014).

Patients with prior biologic exposure at the time of presentation

Table 2. Multivariable logistic regression showing odds

ratios for association with colectomy

Odds

had an increased odds of colectomy (OR 3.48, p=0.008)

1.27 8.20 1.21 3.05 7.73 Female sex 0.018 1.39 8.71 3.48 0.008 Prior biologic exposure 0.19 1.25 0.49 0.138 PO steroids on presentation

CONCLUSIONS

- In our cohort, approximately one fifth of patients with acute severe UC required a colectomy.
- Female sex, hemoglobin <12 g/dl, and prior biologic exposure were independently associated with a higher risk of colectomy.
- Lower hemoglobin and prior biologic use could impact treatment outcomes with inpatient infliximab use. However, it is unclear why there is a gender difference in outcomes.